Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
Generic Drug Price Hikes And Out-Of-Pocket Spending For Medicare Beneficiaries
The share of generic drugs that at least doubled in price increased fourfold according to the Health Affairs study. But, this share is still a small percentage of the generic market.
Posted in -
Do Price Spikes on Some Generic Drugs Indicate Problems in the Generics Market?
Despite the overall success of the generic drug market, sudden price hikes are becoming more common according to new Schaeffer Center study
-
When We Find a Cure, Price it Like Netflix to Ensure Access
Dana Goldman and his colleagues have shown that such subscription models can improve outcomes and save money at the same time.
-
An Economist’s Change of Heart: It’s Time to Regulate the Prescription- Drug Middlemen
Pharmacy-benefit managers find ways to boost their bottom line at the expense of employers and patients, writes Geoffrey Joyce in Market Watch.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
Medicare’s ‘Catastrophic Insurance’ Can Be a Catastrophe for Middle-Income Seniors
Even with Medicare’s catastrophic insurance, middle-income seniors can be on the hook for thousands of dollars for their medications each year, write Erin Trish and Geoffrey Joyce in STAT.
Categorized in -
Who Wins When a Prescription Copay Exceeds the Drug Price? (Not the Patient)
Use an interactive graph to see how frequently a co-payment exceeds the price of commonly prescribed drugs and the average size of the overpayment.
-
Cultivating a Vibrant U.S. Market for Biosimilars: a Conversation with FDA’s Scott Gottlieb
Biosimilars have been a major focus of the FDA’s efforts to increase competition and choice for patients and the U.S. healthcare system.
-
Productivity Benefits of Medical Care: Evidence from US-Based Randomized Clinical Trials
Drug innovation in the last decade increased productivity by 4.8 million work days, resulting in $221 billion in annual wages.
Categorized in -
Economics of the Pharmaceutical Industry
Darius Lakdawalla reviews the economics literature on the pharmaceutical industry, focusing particularly on its positive and normative implications for the innovation, pricing, and marketing decisions of pharmaceutical firms.
Categorized in -
New Payment Strategy Could Help States Treat More Hepatitis C Patients While Encouraging Innovation
A curative treatment exists for chronic hepatitis C infection, yet many Medicaid beneficiaries do not have access to these drugs. Neeraj Sood and his colleagues have developed a novel pricing strategy to expand access.